Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

XOMA Royalty Corp declares dividends and sets redemption date

Xoma Royalty said its board approved quarterly cash dividends on both classes of perpetual preferred stock and set a July 14 redemption date for all outstanding preferred shares.

Holders of the 8.625% Series A cumulative perpetual preferred stock will receive $0.53906 per share, while holders of the 8.375% Series B cumulative perpetual preferred stock will receive $0.52344 per depositary share. The dividends are payable on or about July 15 to stockholders of record at the close of business on July 2.

The company also said it will redeem all outstanding preferred stock on July 14 at $25.00 per share for Series A and $25.00 per depositary share for Series B. Xoma said there are 984,000 Series A shares outstanding and 1,760,500 Series B depositary shares outstanding.

In addition, Xoma set July 13 at 5:00 p.m. Eastern as the record date for contingent value rights tied to the pending merger. Each holder of record of Xoma common stock as of that date will receive one CVR per share as part of the merger consideration.

The redemption and CVR record-date announcements come in connection with Xoma’s pending merger with Ligand Pharmaceuticals and Flex Merger Sub. Following these announcements, the company's shares moved -0.02%, and are now trading at a price of $41.79. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS